Polycystic ovary syndrome

Obstetrics and Gynecology

Volumn 103, Issue 1, 2004, Pages 181-193

  Guzick, David S ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMIFENE CITRATE; GONADOTROPIN; METFORMIN; ORAL CONTRACEPTIVE AGENT; SPIRONOLACTONE;

ANAMNESIS; BODY WEIGHT; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DIET THERAPY; DISEASE ASSOCIATION; DOSE RESPONSE; FERTILIZATION IN VITRO; GASTROINTESTINAL TOXICITY; HEALTH BEHAVIOR; HIRSUTISM; HUMAN; INFERTILITY; LACTIC ACIDOSIS; MENSTRUAL IRREGULARITY; OBESITY; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; WEIGHT REDUCTION; DECISION TREE; ECHOGRAPHY; FEMALE; METHODOLOGY; PREGNANCY;

DECISION TREES; FEMALE; FERTILIZATION IN VITRO; HUMANS; POLYCYSTIC OVARY SYNDROME; PREGNANCY;

EID: 1242308975     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000104485.44999.C6     Document Type: Review

References (37)

1. Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 1935;29:181-91.
2. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseletine FP, Merriam GR, editors. Polycystic ovary syndrome. Boston (MA): Blackwell Scientific Publications; 1992. p. 377-84.
3. Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrin Metab 1998;83:3078-82.
4. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-74.
5. Achard C, Thiers J. Le Virilisme Pilaire et son association à l'insuffisance glylotytique (diabetes des femmes à barbe). Ball Acad Nat Med (Paris) 1921;86:51-64.
6. Kahn CR, Flier JS, Bar RS, Archer JA, Corden P, Martin MM, et al. The syndromes of insulin resistance and acanthosis nigricans. N Engl J Med 1976;294:739-42.
7. Barbieri RL, Ryan KJ. Hyperandrogenism, insulin resistance and acanthosis nigricans syndrome: a common endocrinopathy with distinct pathophysiologic features. Am J Obstet Gynecol 1983;147:90-101.
8. Nestler JE, Barlascini CO, Matt DW, Steingold KA, Plymate SR, Clore JN, et al. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 1989;68:1027-32.
9. Geffner ME, Kaplan SA, Bersch N, Golde DW, Landaw EM, Chang RZ. Persistence of insulin resistance in polycystic ovarian disease after inhibition of ovarian steroid secretion. Fertil Steril 1986;45:327-33.
10. Knobil E. On the control of gonadotropin secretion in the rhesus monkey. Recent Prog Horm Res 1974;30:1-46.
11. Yen SS, Lasley BL, Wang CF, Leblanc H, Siler TM. The operating characteristics of the hypothalamic-pituitary system during the menstrual cycle and observations of biological action of somatostatin. Recent Prog Horm Res 1975;31:321-63.
12. Kalro BN, Loucks TL, Berga SL. Neuromodulation in polycystic ovary syndrome [review]. Obstet Gynecol Clin North Am 2001;28:35-62.
13. Erickson GF, Magoffin DA, Dyer CA, Hofeditz C. The ovarian androgen producing cells: a review of structure/function relationships. Endocr Rev 1985;6:371-99.
14. Rabin D, Spitz I, Bercovici B, Bell J, Laufer A, Benvieniste R, et al. Isolated deficiency of follicle-stimulating hormone. N Engl J Med 1972;287:1313-7.
15. Matthews CH, Borgato S, Beck-Peccoz P, Adams M, Tone Y, Gambino G, et al. Primary amenorrhea and infertility due to mutation in the β subunit of follicle-stimulating hormone. Nat Genet 1993;5:83-6.
16. Almahbobi G, Anderiesz C, Hutchinson P, McFarlane JR, Wood C, Trounson AO. Functional integrity of granulosa cells from polycystic ovaries. Clin Endocrinol (Oxf) 1996;44:571-80.
17. Zeleznik AJ, Kubik CJ. Ovarian responses in macaques to pulsatile infusion of follicle-stimulating hormone and luteinizing hormone: increased sensitivity of the maturing follicle to FSH. Endocrinology 1986;119:2025-32.
18. van Weissenbruch MM, Schoemaker HC, Drexhage HA, Schoemaker J. Pharmacodynamics of human menopausal gonadotropins (hMG) and follicle-stimulating hormone (FSH): the importance of FSH in initiating follicle growth in polycystic ovary-like disease. Human Reprod 1993;8:813-21.
19. Ferriman D, Gallway JD. Clinical Assessment of body hair growth in women. J Clin Endocrinol Metab 1961;21:1440-7.
20. Azziz R, Hincapie LA, Knochenhauer ES, Dewailly D, Fox L, Boots LR. Screening for 21-hydroxylase-deficient non-classic adrenal hyperplasia among hyperandrogenic women: a prospective study. Fertil Steril 1999;72(5):915-25.
21. Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endrocrinol Metab 1987;65:499-507.
22. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-9.
23. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985;61:946-51.
24. Wild RA, Alaupovic P, Givens JR, Parker IJ. Lipoprotein abnormalities in hirsute women. II. Compensatory responses of insulin resistance and dehydroepiandrosterone sulfate with obesity. Am J Obstet Gynecol 1992;167:1813-8.
25. Slowinska-Srzednicka J, Zgliczynski S, Wierzbicki M, Srzednicki M, Stopinska-Gluszak U, Zgliczynski W, et al. The role of hyperinsulinemia in the development of lipid disturbances in nonobese and obese women with the polycystic ovary syndrome. J Endocrinol Invest 1991;14:569-75.
26. Talbott E, Guzick D, Clerici A, Berga S, Detre K, Weimer K, et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler Thromb Vasc Biol 1995;15:821-6.
27. Talbott EO, Zborowski JV, Sutton-Tyrrell K, McHugh-Pemu KP, Guzick D. Cardiovascular risk in women with polycystic ovary syndrome [review]. Obstet Gynecol Clin North Am 2001;28:111-33.
28. Cibula D, Cilkova R, Fanta M, Poledne R, Zivny J, Skibova J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. Hum Reprod 2000;15:785-9.
29. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998;51:581-6.
30. Huber-Buchholz MM, Carey DGP, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999;84:1470-4.
31. Nader S, Raid-Gabriel MG, Saad M. The effect of desogestrel-containing oral contraceptives on glucose tolerance and leptin concentrations in hyperandrogenic women. J Clin Endocrinol Metab 1997;82:3074-7.
32. Morin-Papunen LC, Vauhkonen I, Koivunen RM, Ruokonen A, Martikainen HK, Tapanainen JS. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2000;85:3161-8.
33. Phipps WR. Polycystic ovary syndrome and ovulation induction [review]. Obstet Gynecol Clin North Am 2001;28:165-82.
34. Nestler JE, Jakubowicz D, Evans W, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338:1876-80.
35. Vandermolen DT, Ratts VS, Evans WS, Stovall DW, Kauma SW, Nestler JE. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001;75:310-5.
36. Lunde O, Djoseland O, Grottum P. Polycystic ovarian syndrome: a follow-up study in fertility and menstrual pattern in 149 patients 15-25 years after ovarian wedge resection. Hum Reprod 2001;16:1479-85.
37. Gjonnaess H. Late endocrine effects of ovarian electrocautery in women with polycystic ovary syndrome. Fertil Steril 1998;69:697-701.